Danish Medicines Agency reimburses hypertension drug
This article was originally published in Scrip
Executive Summary
The Danish Medicines Agency has approved Novartis's Rasilez HCT (aliskiren plus hydrochlorothiazide), for the treatment of hypertension, for general reimbursement. It is the fourth drug the agency has cleared this year.